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1. Introduction
Helicobacter pylori (H. pylori) is a gram negative, microaerophilic spiral bacterium with a clear
role in the pathogenesis of gastric and duodenal ulcer, low grade B cell gastric lymphoma
(MALT lymphoma) and gastric cancer. The bacterium was successfully cultivated by Warren
and Marshall in 1982. Their discovery led to completely different therapeutic approach to
patients with peptic ulcer disease and gastric MALT lymphoma. Despite initial skepticism
concerning H. pylori role in gastric carcinogenesis, in 1991 two epidemiological studies [1,2]
confirmed previously published reports suggesting higher incidence of gastric cancer in H.
pylori infected individuals [3-5]. Furthermore, cohort studies in California, Hawaii and Great
Britain confirmed increased risk for gastric cancer in H. pylori infected individuals. As a result
of accumulated scientific evidence Helicobacter pylori was marked as human carcinogen by
International Agency for Research on Cancer in 1994. Gastric cancer is the third most common
cancer among males and fifth most common among females. The incidence of gastric cancer
is declining in developed countries, but the global burden is rising due to cases occurring in
developing countries. The five-year survival for advanced stage gastric cancer is below 20%
even in developed countries [6].
Different outcomes of Helicobacter pylori infection are to be expected depending on distinct
patterns of gastritis that were identified and described in detail. Namely, antrum-predominant
gastritis leads to duodenal ulcer formation while chronic corpus predominant and multifocal
atrophic gastritis lead to increased risk for gastric cancer formation [7-9].
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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The outcome of Helicobacter pylori infection depends on characteristics of the microorganism,
characteristics of the host and environmental factors.
2. Helicobacter pylori virulence factors
Helicobacter pylori virulence depends on different factors enabling it to colonize gastric mucosa
and induce tissue damage. Epidemiological studies revealed so far six distinct H. pylori strains
(hpEurope, hpEastAsia, hpAsia2, hpAfrica 1, hpAfrica2 and hpNEAfrica) that are related to
geographic regions and correlate well with the incidence of gastric cancer [10].
H. pylori is a highly heterogeneous bacterium [11,12]. Several H. pylori virulence factors are
thought to contribute to gastric cancer development and this review will focus on cytotoxin-
associated gene A and CagA protein (CagA), vacuolating cytotoxin (VacA) and outer inflam‐
matory protein (OipA) (Figure 1) with a brief comment on possible role of duodenal ulcer–
promoting gene (dupA).
Figure 1. Mechanism of Helicobacter pylori induced host cell injury
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2.1. cagA
There are two types of clinical H. pylori isolate: CagA-producing (cagA positive) strains and
CagA-nonproducing (cagA negative) strains. Results of studies obtained on animal model
revealed that gastric cancer developed only in animals infected with cagA positive H. pylori
strains or when CagA protein was artificially introduced into the host [13,14] and authors
concluded that CagA protein was important factor in gastric carcinogenesis. Further investi‐
gations revealed that cagA gene polymorphisms could at least partly explain why only some
cagA positive individuals develop gastric cancer. Namely, there are different number of repeat
sequences located on 3` region of the cagA gene in different H. pylori strains. It is now well
known that sequences of these repeat regions differ significantly between strains isolated in
East Asia and Western strains [15]. Each repeat region of the CagA protein contains Glu-Pro-
Ile-Tyr-Ala (EPIYA) motifs. The first repeat region is termed EPIYA-A and EPIYA-B and
second repeat region EPIYA-C or EPIYA-D segments [11]. Western type CagA has EPIYA ABC,
ABCC or ABCCC, while East Asian CagA has EPIYA ABD segments [11].
CagA protein is composed of a disordered C-terminal region that contains the EPIYA motifs and
a structured N-terminal region with several conserved regions. When the bacterium contacts the
host cell CagA is injected into the host cell via the cag pathogenicity island (cagPAI)-encoded type
IV secretion system (T4SS). Upon injection, CagA is linked to the inner leaflet of the cell mem‐
brane probably via an electrostatic interaction with phosphatidylserine [16]. When injected into
the cytoplasm via the T4SS, CagA can be phosphorylated by the host and alter host cell signal‐
ing in both phosphorylation-dependent and phosphorylation-independent manner. CagA is
phosphorylated on EPIYA motifs [17]. Induction of heme oxygenase 1, which exhibits anti-
inflammatory and antioxidant effects, reduced CagA phosphorylation during H. pylori infec‐
tion of gastric epithelial cells in vitro. However, there is data suggesting that the bacterium
developed a strategy to diminish heme oxygenase 1 gene expression in gastric epithelial cells [18].
Recently it was demonstrated that another protein component of T4SS termed CagL induces
hypergastrinemia, which is a major risk factor for the development of gastric adenocarcino‐
ma [17].
2.2. vacA
VacA induces vacuolation of the host cell, membrane-channel formation, cytochrome c release
from mitochondria leading to apoptosis, induces autophagy and alters host immune response
[17,20,21]. VacA also inhibits T-cell activation and proliferation [22]. All H. pylori strains have
a functional vacA gene. There is a variation in the vacuolating activity among different H.
pylori strains [23] related to differences in the vacA gene structure at the signal (s1 and s2)
region, middle region (m1 and m2) and intermediate (i1 and i2) region. Combination of subtype
of these three regions influences the levels of VacA activity and is related to risks for different
gastrointestinal diseases.
The most cytotoxic are s1/m1 strains, followed by s1/m2 strains, whereas s2/m2 strains have
no cytotoxic activity and s2/m1 strains are rare [24]. Individuals infected with s1 or m1 H.
pylori strains have an increased risk of peptic ulcer or gastric cancer compared with individuals
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infected with s2 or m2 strains [11]. In East Asia most H. pylori strains are s1 type that led to
conclusion (based on epidemiological data) that in East Asia presence of m1 region leads to
increased risk for gastric cancer [11] and its typing is the best marker for gastric cancer risk out
of all vacA regions.
Intermediate region of vacA is identified between s and m regions few years ago. All s1/m1
strains belong to the type i1, and all s2/m2 strains are type i2. Strains tha contain s1/m2 can be
type i1 or i2. Strains with i1 region are more pathogenic. In some populations typing of i-region
is superior in predicting gastric cancer risk than typing of s region, while in other populations
it has no predictive value [25].
The deletion (d) region—was identified between the i-region and the m region [26]. The d
region is divided into d1 and d2. The study of Western strains demonstrated that d1 was a risk
factor for gastric mucosal atrophy; however, almost all East Asian strains are classified as
s1/i1/d1 [11].
2.3. oipA
Outer membrane proteins (OMPs) are coded by different genes in Helicobacter pylori genome.
One of the OMPs that can function as adhesin is OipA, which was identified in 2000 [11].
OipA is a protein that induces proinflammatory response and its activity leads to increase in
mucosal interleukin-8 (IL8) levels. OipA is involved in the attachment of H. pylori to gastric
epithelial cells in vitro [27]. Results from animal studies demonstrated that OipA alone plays
a role in the development of gastric cancer [13].
The production of CagA, VacA and OipA is linked and the majority of H. pylori strains produce
either all of these proteins or none of them. Almost all East Asian strains of H. pylori are
classified as CagA-producing, VacA-producing (vacA s1), and OipA-producing strains and are
highly pathogenic. In addition, CagA, VacA and OipA are all thought to be involved in the
development of both gastric cancer and duodenal ulcer [11].
2.4. dupA
Duodenal ulcer–promoting gene dupA was described in 2005. It is localized in the plasticity
zone and it is involved in T4SS formation. Initial report suggested it to be the first disease-
specific H. pylori virulence factor that induced duodenal ulcer formation and had a suppressive
action on gastric cancer (DupA) [28]. After this report multiple studies failed to demonstrate
correlation between dupA gene and specific gastroduodenal disease [10,29,30]. This gene
is,however, highly polymorphic, and that could explain the conflicting data obtained in
different studies [17].
2.5. Geographic differences in gastric cancer incidence related to Helicobacter pylori strains
Multilocus sequence typing (MLST) of the housekeeping genes revealed six H. pylori strains
(hpEurope, hpEastAsia, hpAsia2, hpAfrica 1, hpAfrica2 and hpNEAfrica) that are related to
geographic regions and correlate well with the incidence of gastric cancer.
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Sequence differences among the examined housekeeping genes of the six major genotypes
probably have no influence on the disease outcome but serve as a marker for other virulence
factors related to the disease outcome (i.e cagA and vacA) [10]. In 2003, Falush et al analyzed
370 H. pylori isolates and assigned the strains to four main clusters: hpEurope, hpEastAsia,
hpAfrica1 and hpAfrica2 due to their obvious geographical associations [31]. HpEurope is
common in Europe and countries colonized by Europeans and most isolates from East Asia
belong to hpEastAsia. HpAfrica2 is very distinct and has only been isolated in South Africa.
Four years later Linz et al expanded the analysis using 769 H. pylori isolates and assigned the
isolates to six distinct groups, adding to previously descried clusters (hpEurope, hpEastAsia,
hpAfrica1 and hpAfrica2) two new clusters termed hpAsia 2 and hpNEAfrica. Cluster hpAsia2
was isolated in South and Southeast Asia. Cluster hpNEAfrica is predominant among isolates
from Northeast Africa [12].
Populations with high rates of gastric cancer correspond with regions presenting hpEastAsia
strains. In contrast, incidence of gastric cancer is very low in Africa, where most strains are
hpNEAfrica, hpAfrica1 or hpAfrica2, and in South Asia, where most strains are hpAsia2. The
differences in H. pylori isolates in different populations are considered to be an explanation of
the both African and Asian enigma. Namely, populations with high incidences of Helicobacter
pylori infection in East Asian countries have high incidences of gastric cancer, as opposed to
low incidence of gastric cancer in other highly infected populations in Africa (African enigma)
and South Asia (Asian enigma) [10].
3. Host factors
Host characteristics and immune response to Helicobacter pylori infection also play a role in
gastric carcinogenesis. Different gene polymorphisms that affect host immune response and
extent of cell proliferation are described and linked to gastric carcinogenesis together with
gene polymorphisms for growth factors and growth factor receptors. Majority of these
polymorphisms are single nucleotide polymorphisms (SNP). In recent years, host genetic
polymorphisms involved in inflammatory response, carcinogen metabolism, antioxidant
protection, mucosal protection and cell proliferation regulation have been widely studied as
potential biomarkers to predict gastric cancer risk.
4. Cytokine gene polymorphisms
Cytokines modulate inflammatory response to Helicobacter pylori infection and indirectly the
risk for gastric cancer. Gene polymorphisms for interleukin-1 beta and its receptor antagonist,
tumor necrosis factor alpha, interleukin-8 and interleukin-10 were extensively studied and
reported as relevant in determining gastric cancer risk.




Interleukin-1 beta (IL-1β) is a potent inhibitor of gastric acid secretion. Reduced gastric acid
secretion on the other hand promotes development of H. pylori induced pangastritis, gastric
mucosa atrophy and subsequently, in a subset of individuals, gastric cancer development. El-
Omar et al described in 2000 polymorphisms in the pro-inflammatory IL-1B gene (encoding
IL-1β) and IL-IRN (encoding IL-1β receptor antagonist) associated with elevated risk for
hypochlorhydria and gastric cancer in the persons with H. pylori infection [32] (El-Omar).
Presence of IL-1B-31C or -511T and IL-IRN*2/*2 polymorphisms is associated with a 2-3-fold
increase in risk for intestinal and diffuse non-cardia gastric cancer among H. pylori-infected
persons [33]. These genetic polymorphisms modulate gastric cancer risk by increasing
expression of pro-inflammatory cytokine IL-1β. It was later established that these polymor‐
phisms interact synergistically with bacterial virulence factors (cagA positive, vacA s1 and vacA
m1). Gastric cancer risk is highest among those with both host and bacterial high-risk geno‐
types [34].
Results of meta-analysis provided by Persson et al. based on available data from epidemio‐
logical studies showed strongest association of IL1RN2 polymorphism with increased risk for
gastric cancer [35] in non-Asian populations for both intestinal and diffuse cancers. The
IL1RN22 genotype has been reported to cause high circulating IL-1receptor antagonist and
IL-1β levels resulting in a severe and prolonged inflammatory response. IL1B-511T carriers
were found to have an increased risk of gastric cancer in non-Asian populations. Possible
explanation is that stronger inflammatory reaction may increase the risk of cancer through
damage to gastric cells and bacterial overgrowth and accumulation of toxic byproducts [32].
These findings are supported by results of some [36,37], but not all previously published meta-
analysis [38]. Surprisingly, according to Persson et al IL-1B-31C polymorphism was associated
with a reduced overall risk for gastric cancer in Asian populations [35].
4.2. Tumor necrosis factor alpha
Tumor necrosis factor alpha (TNF-α) is another proinflammatory cytokine produced in gastric
mucosa in response to H. pylori infection. Polymorphisms in TNF-A gene, especially presence
of the high producing A allele of TNF-A at position 308 (G→A) is considered to be associated
with increased risk for non-cardia gastric cancer [6]. This finding is supported by majority
[39-41], but not all of available meta-analysis [35].
4.3. Interleukin 10
Interleukin 10 is an anti-inflammatory cytokine that down-regulates IL-1B, TNF-A, and
interferon-γ gene expression. Previously published studies suggested that individuals
carrying the IL-10 ATA haplotype associated with low IL-10 production (-592, -819, -1082) have
an increased risk for non-cardia gastric cancer [33]. Nevertheless meta-analysis failed to
confirm these observations except for IL10-1082G where the effect of polymorphism depends
on ethnicity of the host. It seems that this polymorphism increases gastric cancer risk in Asians,
but has no significant effect in non-Asian populations [39].
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4.4. Interleukin 8
IL-8 is a CXC family cytokine that is a potent chemoattractant for neutrophils and lymphocytes
affecting proliferation, migration, and tumor angiogenesis. However, not all studies have
replicated the positive associations between pro-inflammatory cytokines polymorphisms and
gastric cancer risk [42]. A polymorphisms in IL-8 (-251 T→A) is associated with increased
production of IL-8 in H. pylori infected gastric mucosa and with precancerous gastric abnor‐
malities in Caucasians and gastric cancer in Asian populations [43]. Nevertheless, studies in
Asian populations [44,45] have failed to confirm relevance of this polymorphism and meta-
analysis supported this finding [35], but this can be attributable to small sample size in these
studies and limited number of the high quality studies available for the meta-analysis.
4.5. Presence of multiple high-risk cytokine gene polymorphisms
Possession of multiple high-risk host polymorphisms is associated with increased risk for
gastric cancer. Presence of 3-4 of the polymorphisms (IL-B1-511*T, IL-IRN*2/*2, TNF-A-308*A
and IL-10 ATA/ATA) confers a 27-fold increase in risk of non-cardia gastric cancer [33].
5. Polymorphisms in innate immune response genes
H. pylori attaches to gastric epithelium via receptors. Thus, polymorphisms in the innate
immune response genes, which interact with these receptors, could influence outcome of
infection and potentially the risk of gastric cancer.
5.1. Toll like receptor 4 (TLR4)
TLR4 is a cell-surface signaling receptor involved in the recognition and host response to
Helicobacter pylori. Toll-like receptor 4 gene codes for a lipopolysaccharide (LPS) receptor
molecule involved in innate immune recognition of microbe pathogen-associated molecular
patterns. The TLR4+896A>G polymorphism linked with impaired reactivity to bacterial
lipopolysaccharide may play a role in gastric carcinogenesis [44] and is associtaed with
hypochlorhydria and upper gastrointestinal cancer. TLR4 896 polymorphisms results in
changed conformation of the extra cellular domain of the TLR4 receptor and carriers are unable
to adequately respond to LPS challenge. The defective signaling through TLR4 leads to an
exaggerated inflammatory response with severe tissue destruction that causes gastric atrophy
and severe hypochlorhydria. Two independent case-control studies have demonstrated that
TLR4+896G carriers have eightfold increase in odds ratio for hypochlorhydria and gastric
atrophy, and over two-fold increase for gastric cancer [44,45]
6. Cell proliferation-related gene polymorphisms
Meta-analysis by Gao et al identified 23 polymorphisms significantly related to gastric cancer
in at least one published study suggesting the importance of polymorphisms in genes
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implicated in cell proliferation in development of gastric cancer. The overall effect of these
polymorphisms is probably modest but should not be neglected [46].
6.1. Cell cycle and apoptosis regulators
Cell cycle and apoptosis regulators are directly involved in the initiation of malignant
proliferation of the cell. Polymorphisms of functional regulators of TP53, TP53BP2 (tumor
protein P53 binding protein 2) and MDM2 (gene encoding Mouse double minute 2 homolog,
an important negative regulator of the p53 tumor suppressor) were found to be related to the
development of gastric cancer. TP3 gene encodes a multi-purpose protein (P53) that takes part
in regulating the cell cycle, carrying out programmed cell death, initiating DNA repair, and
regulating the transcription of a large number of genes that cells use for various biological
purposes. Given its many essential functions, P53 is frequently found inactivated in tumor
cells. Results of meta-analysis confirm that association of TP3 gene polymorphisms vary by
population and type of gastric cancer. The TP3 Arg allele carriers of Asian origin have an
increased risk for gastric cancer, while same polymorphism seems to have protective effects
in Caucasians [43]. Possible explanation is difference in environmental factors that act together
with either apoptotic or DNA repairing mechanisms. Data obtained for other two polymor‐
phisms in cell-cycle related genes that were extensively studied are inconsistent, both for Lmyc
(nuclear oncogen) EcoRI polymorphism and p21 (gene encoding P21/ cyclin-dependent kinase
inhibitor 1) polymorphism (Arg31Ser), probably due to relatively small sample sizes and
underestimated importance of environmental factors and their interplay with host genetics.
PPAR-γ (peroxisome proliferator-activated receptors γ) is a member of the nuclear hormone
receptor family that plays an important role in cell differentiation and regulation of metabo‐
lism. A potential interplay between PPAR-γ Pro12Ala polymorphism and H. pylori infection
was observed in the development of gastric cancer [47,48].
6.2. Growth factors and growth factor receptors
Polymorphisms determining higher level of growth factors and related receptors, which are
important for tissue repair, were associated with reduced risk of gastric cancer. Such associa‐
tions were observed for gene encoding epidermal growth factor (EGF) EGF 5′ UTR 61G>A,
[49], polymorphisms for transforming growth factor beta (TGFB) i.e. TGFB1 -509C>T,
TGFBR2-875G>A [50] and gene encoding insulin-like growth factor-binding protein 3 IGFBP3
-202A>C and Gly32Ala [51,52].
7. Environmental factors
Environmental regulation of virulence factors could be an interesting concept explaining why
not all infected individuals develop severe complications of disease despite infection with
pathogenic Helicobacter pylori strains.
Recent study demonstrated that high salt diet could influence H. pylori protein expression [53].
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7.1. Diet
In 2007 World Cancer Research Fund declared that high intake of vegetables and fruit probably
decrease risk of gastric cancer, and that high intakes of salt and salty food probably increase
risk of gastric cancer [54]. The proposed underlying mechanism for the inverse association of
gastric cancer risk with vegetable and fruit/rich diet is related to the presence of antioxidants.
Salt on the other hand acts directly on the stomach lining, destroying the mucosal barrier,
causes gastritis and increased epithelial cell proliferation [55]. A synergistic interaction
between diet and Helicobacter pylori infection with risk of gastric cancer has been proposed [56].
Recent study demonstrated that high salt diet could influence Helicobacter pylori protein
expression leading to increased risk of gastric cancer [53]. Salt responsive increase in cagA
expression attributable to increased CagA transcription was described that could lead to
increased risk of gastric cancer.
7.2. Smoking
Tobacco smoking is the risk factor associated with the largest number of cancer cases world‐
wide and the causal link with stomach cancer is recognized [54]. A recent meta-analysis found
significant positive associations of smoking with risk of both cardia and non-cardia gastric
cancer among the majority of studies, overall increasing risk by 62% for male and 20% for
female current smokers [57]. It is possible that tobacco smoke carcinogens affect gastric cancer
risk directly through contact with the stomach mucosa or indirectly through the blood flow
[54]. In a large population-based study in Europe (EPIC), 17.6% of gastric cancer cases were
attributed to smoking [56]. The cancer risk in past smokers can remain up to 14 years after
cessation of smoking [57,58]. The effect of smoking on gastric cancer is dose-dependent and
additive in the presence of other risk factors [59,60]. However, passive smoking does not seem
to increase the risk [61].
7.3. Non-steroidal anti-inflammatory drugs
Protective effect of regular use of non-steroidal anti-inflammatory drugs (NSAIDs) and
particularly aspirin on risk of gastric cancer was repeatedly reported in observational studies
and then results of meta-analysis [62] confirmed these finding. According to Algra et al regular
NSAID users have up to 20% reduced risk of gastric cardia adenocarcinoma and up to 36%
reduced risk of distal gastric adenocarcinoma [62]. NSAIDs suppress the production of
cyclooxygenase enzymes. Data on clinical efficacy of NSAIDs in prevention of gastric cancer
first suggested that aspirin reduces risk for both proximal and distal gastric cancer [63]. Recent
results from population-based intervention trial by Wong et al revealed that celecoxib
treatment or Helicobacter pylori eradication alone had beneficial effects on the regression of
advanced gastric lesions. Nevertheless no favourable effects were seen for H. pylori eradication
followed by celecoxib treatment [64]. Meta-analysis by Tian et al suggests significant protective
effects of NSAIDs against gastric cancer [65].




Lower socioeconomic status is associated with at least two-fold greater risk of gastric cancer
irrespective of the country incidence of gastric cancer [54]. Possible explanation is related to
increased likelihood of transmission and re-infection with H. pylori (large family, poor
sanitation, less frequent use of antibiotics). Also, low socioeconomic status is related to a diet
lower in fresh fruits and vegetables.
8. Importance of Helicobacter pylori eradication in prevention of gastric
cancer development-current knowledge and evidence
Helicobacter pylori infection is mainly associated with distal forms and intestinal-type gastric
carcinoma [7-9]. Namely, there are two distinct sites of gastric adenocarcinoma: proximal
(cardia) and distal (non-cardia), with different epidemiological and clinical characteristics.
Main risk factors for cardia gastric cancer are obesity, gastro-oesophageal reflux disease and
Barrett’s oesophagus [66] and its incidence is increasing over last decades. On the contrary,
main risk factors for development of distal gastric cancer are H.pylori, low socioeconomic
status, smoking, salty and smoked food intake, low consumption of fruits and vegetables and
a family history of gastric cancer. Clear decline in incidence of distal gastric cancer is observed
in the last decades [67].
Histologically gastric cancer is, according to Lauren classification, divided into two subtypes:
intestinal and diffuse type. The intestinal type is related to corpus-predominant gastritis with
intestinal metaplasia and is closely related to long-lasting H.pylori infection, whereas the
diffuse originates from superficial pangastritis without atrophy [7-9].
Intestinal type gastric adenocarcinoma results from a prolonged precancerous process. The
link between gastric intestinal metaplasia and cancer was proposed by pathologists in Java
and Sumatra in 1938. This idea was over time only occasionally revisited by scientists until in
1975 Correa et al proposed a model of gastric carcinogenesis. This model postulated that
intestinal type of gastric cancer was a result of progressive changes in the gastric mucosa [68].
Authors updated their model in 1988 and 1992. In Correa cascade the following consecutive
steps are now recognized: normal gastric mucosa, superficial (non-atrophic) gastritis, multi‐
focal atrophic gastritis (MAG), complete (small intestine type) intestinal metaplasia followed
by intestinal metaplasia of the incomplete (colonic) type, low-grade dysplasia, high-grade
dysplasia and invasive adenocarcinoma. [7-9, 68]. Loss of normal glandular tissue is the first
specific recognizable step in the precancerous cascade. However, the changes of the precan‐
cerous lesions over time remain an issue difficult to assess leading to the fact that the point of
no return, although of critical importance for timely eradication, still remains unidentified.
Five randomized controlled trials (RCT) reported effects of H.pylori infection eradication on
invasive gastric cancer or premalignant histological lesions of gastric mucosa. [69-75]
Study by Wong et al. was designed as RCT conducted in a high-risk gastric cancer region in
China that evaluated gastric cancer incidence as a primary outcome [69]. Authors identified
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healthy individuals with H. pylori infection and treated them either with eradication therapy
or placebo. During a follow-up period of 7.5 years authors failed to demonstrate overall
decrease in gastric cancer incidence. The study concluded that incidence of gastric cancer
development in the general population was similar between subjects receiving H. pylori
treatment and placebo. The study, however, suggested the possible protective role of H.
pylori eradication in participants without precancerous lesions, including gastric atrophy,
intestinal metaplasia, or dysplasia.
Other above cited trials were not designed to assess gastric cancer as a primary outcome [70,
71] or had low numbers of gastric cancer cases [69, 72] to provide an informative assessment
of the effects of eradication on cancer occurrence. Nevertheless, recently an important study
was published by Ma et al [74] with the long-term follow-up results of a randomized trial in
which 2258 H. pylori seropositive adults from a general population in China were randomly
assigned to three interventions (H. pylori eradication, garlic supplements, supplemental
vitamins) or control groups. After 15 years there were 34 new gastric cancers in H. pylori
eradication group and 52 in the corresponding control group (relative risk of 0.61, 95 %
confidence interval 0.38-0.96) that clearly demonstrated benefit of eradication therapy in
gastric cancer prevention.
This year Lee et al [76] evaluated the benefit of mass eradication of H. pylori infection started
in Taiwanese population with high incidence of H. pylori infection. Individuals who were aged
30 years and older were tested for the presence of H. pylori infection and those positive
underwent endoscopic screening and subsequent eradication therapy. Authors demonstrated
the success of eradication in 78.7%. Gastric atrophy incidence decreased in over 77% after
successful eradication of H. pylori with no significant change in intestinal metaplasia. Gastric
cancer incidence during the chemoprevention period was reduced by 25%. Based on these
findings authors suggest that ultimate benefit in reducing gastric cancer incidence and its
mortality should be validated by a further long-term follow-up.
Over a decade ago Uemura et al. [77] first reported that H. pylori eradication could reduce the
subsequent development of metachronous gastric cancer after endoscopic resection of early
gastric carcinoma. Namely, 132 H. pylori serology-positive patients who underwent endo‐
scopic resection were assigned to the H. pylori-treatment group or the no treatment group
according to the patients’ preference. Regular endoscopic follow-up for up to 4 years found
no metachronous cancer in H. pylori-treated patients compared to 9% in the no treatment
group.
Some years later, Fukase et al. [75] reported the results of a trial in which more than five
hundred patients in Japan who had previously undergone endoscopic resection for treatment
of early gastric cancer were randomized to either H. pylori eradication or usual care. They
demonstrated statistically significant 65 % reduction in the risk of metachronous gastric
carcinoma compared with the control group.
The evidence from more recent trial reports [74-76], taken together with the epidemiological
and experimental evidence for the carcinogenic activity of chronic H. pylori infection, provides
support for a protective effect of H. pylori eradication in gastric cancer.




H. pylori infection contributes 5.5% to global cancer burden and is the single most important
cause of infection-associated cancer globally [6]. It is therefore reasonable to consider eradi‐
cation therapy as optimal preventive approach in infected individuals. Interrupting transmis‐
sion of infection is primary prevention, secondary should be eradication therapy and tertiary
prevention includes identification of the individuals with early gastric cancer. However data
from large study in China that included 1630 healthy carriers of H. pylori infection that were
given eradication therapy or placebo detected no difference of gastric cancer incidence between
these two groups [69]. Benefit would probably be seen in patients where gastric cancer cascade
did not cross the point of no return, which would explain results of recently published studies
[74,76]. Namely, intestinal-type gastric cancer results from a multistep process of mucosal
alterations leading from chronic inflammation (gastritis) to glandular atrophy followed by
development of intestinal metaplasia and dysplasia resulting in invasive carcinoma. Clinical
studies should aim to identify a 'point of no return', a situation when mucosal alterations are
no longer reversible after H. pylori eradication and progression to gastric cancer became
independent of presence of the bacterium.
Higher risk for gastric cancer might be modulated by an overall pro-inflammatory host genetic
profile in the adaptive and innate immune systems genes (e.g. IL-1B, TNFA, IL-10, IL-8, and
TLR4) [77]. This pro-inflammatory profile might drive the immune response to H. pylori
infection to a severe chronic inflammatory phenotype, reduced gastric acid secretion, bacterial
overgrowth, and oxidative stress to the gastric mucosa.
Therefore timely eradication of H pylori infection especially in individuals with proinflamma‐
tory genetic profile could prevent development and in long term possibly decrease incidence
of gastric cancer.
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